Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of damaged tissues in the human body. An induced pluripotent stem cells, or iPSCs, are taken from any tissue (usually skin or blood) from a child or an adult and is genetically modified to behave like pluripotent stem cells or embryonic stem cells.
iPSCs market is in emerging state mainly due to its ability to make any cell or tissue the body might need to encounter wide range of diseases like diabetes, spinal cord injury, leukaemia or heart disease, these cells can potentially be customized to provide a perfect genetic match for any patient.

Market Analysis and Insights: Global Induced Pluripotent Stem Cells Market
The global Induced Pluripotent Stem Cells market size is projected to reach US$ 92 million by 2026, from US$ 82 million in 2020, at a CAGR of 12.2%% during 2021-2026.

Global Induced Pluripotent Stem Cells Scope and Market Size
Induced Pluripotent Stem Cells market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Induced Pluripotent Stem Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study

Fujifilm Holding Corporation
Astellas Pharma
Fate Therapeutics
Bristol-Myers Squibb Company
ViaCyte
Celgene Corporation
Aastrom Biosciences
Acelity Holdings
StemCells
Japan Tissue Engineering
Organogenesis

Market segment by Type, the product can be split into

Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others

Market segment by Application, split into

Academic Research
Drug Development And Discovery
Toxicity Screening
Regenerative Medicine

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India